Compare Innodata Inc (INOD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Innodata Inc trades at $63.13 (market cap $2.05B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 65.5× Innodata Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| INOD | VRTX | |
|---|---|---|
Market Cap | $2.05B | $134.25B |
Sector | Technology | Health |
52-Week High | $121.50 | $529.65 |
52-Week Low | $34.45 | $376.62 |
Enterprise Value | $1.80B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $62.33, down 4.81% over 24 hours, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.41 versus $0.21 expected, driven by 58% revenue growth and AI demand expansion. Valuation ratios remain elevated, with a P/E of 48.24 and P/S of 6.79, reflecting high growth expectations. Recent news highlights AI-driven growth and leadership transition plans.
Outlook is positive due to robust AI momentum and earnings beats, but risks include premium valuation and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside from current levels. Investors should weigh growth potential against execution risks in a competitive AI services market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
